Blair William & Co. IL Sells 980 Shares of Glaukos Corp (GKOS)

Blair William & Co. IL lowered its stake in shares of Glaukos Corp (NYSE:GKOS) by 3.5% during the third quarter, HoldingsChannel reports. The firm owned 26,730 shares of the medical instruments supplier’s stock after selling 980 shares during the quarter. Blair William & Co. IL’s holdings in Glaukos were worth $1,735,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Segall Bryant & Hamill LLC purchased a new stake in Glaukos in the second quarter valued at about $929,000. Seven Eight Capital LP purchased a new stake in Glaukos in the third quarter valued at about $1,090,000. Waddell & Reed Financial Inc. raised its stake in Glaukos by 68.4% in the second quarter. Waddell & Reed Financial Inc. now owns 1,115,815 shares of the medical instruments supplier’s stock valued at $45,346,000 after buying an additional 453,167 shares during the last quarter. Artisan Partners Limited Partnership raised its stake in Glaukos by 0.7% in the second quarter. Artisan Partners Limited Partnership now owns 426,246 shares of the medical instruments supplier’s stock valued at $17,323,000 after buying an additional 2,845 shares during the last quarter. Finally, Novo Holdings A S raised its stake in Glaukos by 6.6% in the second quarter. Novo Holdings A S now owns 602,709 shares of the medical instruments supplier’s stock valued at $24,494,000 after buying an additional 37,544 shares during the last quarter.

In other news, CFO Joseph E. Gilliam sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $60.03, for a total value of $300,150.00. Following the completion of the transaction, the chief financial officer now directly owns 86,117 shares in the company, valued at $5,169,603.51. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Joseph E. Gilliam sold 2,100 shares of the firm’s stock in a transaction dated Monday, November 26th. The stock was sold at an average price of $58.37, for a total value of $122,577.00. Following the completion of the transaction, the chief financial officer now owns 91,117 shares of the company’s stock, valued at $5,318,499.29. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 63,075 shares of company stock valued at $3,653,652. Company insiders own 11.60% of the company’s stock.

A number of equities research analysts have commented on GKOS shares. Stephens reiterated an “overweight” rating and issued a $57.00 price target on shares of Glaukos in a research note on Wednesday, August 29th. JPMorgan Chase & Co. upgraded Glaukos from a “neutral” rating to an “overweight” rating and increased their price target for the company from $42.00 to $75.00 in a research note on Wednesday, August 29th. ValuEngine upgraded Glaukos from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 29th. BMO Capital Markets increased their price target on Glaukos from $59.00 to $62.00 and gave the company a “market perform” rating in a research note on Thursday, August 30th. Finally, Wells Fargo & Co increased their price target on Glaukos from $50.00 to $74.00 and gave the company an “outperform” rating in a research note on Thursday, August 30th. Four analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Glaukos has an average rating of “Buy” and an average price target of $58.20.

Shares of NYSE:GKOS opened at $66.52 on Friday. Glaukos Corp has a 52-week low of $23.08 and a 52-week high of $70.91.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, November 7th. The medical instruments supplier reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.05). Glaukos had a negative return on equity of 9.26% and a negative net margin of 8.13%. The firm had revenue of $43.91 million during the quarter, compared to analysts’ expectations of $41.65 million. During the same quarter in the previous year, the business earned $0.04 earnings per share. The company’s revenue for the quarter was up 8.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Glaukos Corp will post -0.55 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Blair William & Co. IL Sells 980 Shares of Glaukos Corp (GKOS)” was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.wkrb13.com/2018/12/07/blair-william-co-il-sells-980-shares-of-glaukos-corp-gkos.html.

Glaukos Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.

Further Reading: What is an SEC Filing?

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corp (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply